AFP welcomes European Commission decision securing its public financing

The European Commission has given its decision on a complaint made in February 2010 by a German news  agency against France for giving state aid to AFP. The decision recognizes the missions of general interest on an international level attributed to AFP and permits the compensation of the net cost by a State subsidy that respects European competition laws. “This decision is a crucial moment for AFP,” said AFP chairman Emmanuel Hoog.

The European Commission has given its decision on a complaint made in February 2010 by a German news  agency against France for giving state aid to AFP. The decision recognizes the missions of general interest on an international level attributed to AFP and permits the compensation of the net cost by a State subsidy that respects European competition laws. “This decision is a crucial moment for AFP,” said AFP chairman Emmanuel Hoog.
Anglais
07/08/2026 12:00
Merck Announces FDA Breakthrough Therapy Designation for Enpatoran in Lupus Patients With Active Skin Manifestations

Merck, a leading science and technology company, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to enpatoran for the treatment of lupus with active cutaneous manifestations. Enpatoran is an oral selective toll-like receptor (TLR) 7/8 inhibitor, designed to modulate pathways central to lupus-related inflammation. “For the 85% of lupus patients whose disease includes skin manifestations, often associated with substantial physical and ...

07/08/2026 12:00
LUMI AI Factory Selects IQM to Deploy Advanced Quantum Computer, Accelerating Hybrid HPC and AI Development

The LUMI AI Factory, led by CSC – IT Center for Science, has selected IQM Quantum Computers (Nasdaq: IQMX) to deliver IQM Halocene H4, an advanced quantum computer aimed at accelerating hybrid high-performance computing, artificial intelligence, and quantum computing capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708006791/en/LUMI AI Factory selects IQM to deploy advanced quantum computer, accelerating hybrid HPC an...

AFP CEO conveys his condolences to Al Jazeera teams after the death of journalist Shireen Abu Akleh

Fabrice Fries, Chairman and CEO at AFP, has conveyed his condolences to Sheikh Hamad bin Thamer Al-Thani, Chairman of the Board for Al Jazeera media network, after the death of journalist Shireen Abu Akleh.

Fabrice Fries, Chairman and CEO at AFP, has conveyed his condolences to Sheikh Hamad bin Thamer Al-Thani, Chairman of the Board for Al Jazeera media network, after the death of journalist Shireen Abu Akleh.
07/08/2026 12:00
STEMCELL Technologies and CCRM Partner to Expand Access to Matched GMP and RUO iPSC Lines for Cell Therapy Development

STEMCELL Technologies and the Centre for Commercialization of Regenerative Medicine (CCRM) today announced a partnership to expand access to high-quality human induced pluripotent stem cell (iPSC) starting materials, giving cell therapy developers worldwide a faster, lower-risk path from research to the clinic. Under the agreement, STEMCELL will manufacture and distribute research-use-only (RUO) iPSC lines derived directly from LineaBio's Good Manufacturing Practices (GMP) iPSC lines, and will ...

07/08/2026 12:00
PubNub Introduces Blocks.ai: The Control Plane and Network Layer For AI Agents

PubNub introduces Blocks.ai today, a global network to connect and control agents across all agent frameworks, providers, and APIs. Blocks.ai lets developers reach their existing AI agents regardless of where they are hosted. Blocks Network supports all AI agent use cases without opening inbound ports, setting up tunnels, changing DNS, or modifying firewall rules. For more than a decade, PubNub has been the infrastructure and platform for real-time connectivity supporting billions of devices, n...

07/08/2026 12:30
Leo Cancer Care Raises $65M Series D to Scale Its Integrated Upright Cancer Care Platform

Leo Cancer Care, the medical technology company working to reinvent how patients are imaged and treated by designing systems around the body’s natural upright position, today announced the close of an oversubscribed $65 million Series D financing. The round was led by Silicon Valley’s Yu Galaxy and welcomes new investors including Eventide Asset Management, alongside continued support from the company’s existing investors. Leading cancer institutions are already adopting the upright approach....

07/08/2026 12:00
Fastly Joins DIMPACT to Collaborate on Digital Sustainability

Fastly, Inc. (NASDAQ: FSLY), a leading global edge cloud platform, today announced it has become a participant of DIMPACT, the coalition of leading organizations working to align industry changemakers and policymakers around meaningful, science-based solutions that reduce the environmental impacts of serving digital media products. As the first edge cloud platform provider to join the coalition, Fastly brings critical, real-world edge network data and infrastructure expertise and a transparen...

07/21/2026 07:00
CapVest Completes Acquisition of TSG

CapVest Partners LLP (“CapVest”), a leading New York and London based investment firm, today announces that it has completed its acquisition of a majority stake in TSG Solutions (“TSG”), a European leader in technical services for critical energy infrastructure, following receipt of all necessary approvals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260721628079/en/TSG Headquartered in Paris, France, TSG operates across 30 count...

07/21/2026 07:00
European Commission Approves Crysvita® (burosumab) for Infants with X-linked Hypophosphataemia in the European Union

Kyowa Kirin EMEA, a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151), today announced that the European Commission (EC) has approved an expansion of the indication for Crysvita® (burosumab) for the treatment of X-linked hypophosphataemia (XLH), to include infants from 1 month to 1 year of age across the European Union and European Economic Area. The approval represents an important step forward for infants living with XLH, a rare, progressive genetic disease that can affect skeleta...